Zoledro-Denk 4 mg / 5 ml


  • One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate)
  • Zoledro-Denk prevents skeletal related events in patients with advanced malignancies involving bone fractures in patients with cancers, and treats tumor-induced hypercalcemia, osteoporosis (post-menopausal women and in men; even with a recent low-trauma hip fracture; also associated with long-term systemic glucocorticoid therapy) and Paget’s disease of the bone
  • Strong inhibition of osteoclastic bone resorption
  • Showed significant benefit in osteoporosis as well as reduction in mortality after hip fraction

Patient Reminder Card